Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 7;29(7):4748-4767.
doi: 10.3390/curroncol29070377.

Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer

Mehrnoosh Pauls  1 , Stephen Chia  1 , Nathalie LeVasseur  1
Affiliations
Review

Current and New Novel Combination Treatments for Metastatic Triple-Negative Breast Cancer

Mehrnoosh Pauls et al. Curr Oncol. .

Abstract

Triple-negative breast cancer (TNBC) has a worse prognosis and remains the most challenging breast cancer subtype to treat. This is largely related to the heterogeneity of this disease and the lack of reliable oncological targets. In this review, we discuss the current standard-of-care treatment options for metastatic TNBC, including recent advances with the use of immunotherapy, PARP inhibitors and antibody-drug conjugates. This review also explores new agents and novel combinations arising in the field for the treatment of advanced TNBC.

Keywords: PARP inhibitor; PI3K/AKT/mTOR; antibody-drug conjugate (ADC); immunotherapy; metastatic TNBC.

PubMed Disclaimer

Conflict of interest statement

M. Pauls reports consulting honoraria and sponsorship from Ipsen, Novartis and Pfizer, all being outside of the submitted work. S. Chia reports honoraria from Novartis, Hoffmann LaRoche, Pfizer, Eli Lilly, Merck, AstraZeneca, Exact Sciences and Gilead. N. LeVasseur reports receiving honoraria for participation in advisory boards from Gilead, Knight, Lilly, Novartis, Pfizer, Roche, Seagen, TerSera and research funds to their institution from Abbvie and Exact Sciences.

Figures

Figure 1
Figure 1
Summarized algorithm for treatment for mTNBC based on current phase III evidence available. * This recommendation is based on meaningful OS among the prespecified subgroup that received olaparib as first-line treatment who had not received prior chemotherapy (HR 0.51, 95% CI 0.29–0.90) in OlympiAD trial.
See this image and copyright information in PMC

References

    1. Gelmon K., LeVasseur N. Triple negative breast cancer–Understanding the clinical implications of heterogeneity. Med. Res. Arch. 2020;8 doi: 10.18103/mra.v8i3.2037. - DOI
    1. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., Lickley L.A., Rawlinson E., Sun P., Narod S.A. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clin. Cancer Res. 2007;13:4429–4434. doi: 10.1158/1078-0432.CCR-06-3045. - DOI - PubMed
    1. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., Pietenpol J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Investig. 2011;121:2750–2767. doi: 10.1172/JCI45014. - DOI - PMC - PubMed
    1. Keenan T.E., Tolaney S.M. Role of Immunotherapy in Triple-Negative Breast Cancer. J. Natl. Compr. Canc. Netw. 2020;18:479–489. doi: 10.6004/jnccn.2020.7554. - DOI - PubMed
    1. Cortes J., Cescon D.W., Rugo H.S., Nowecki Z., Im S.-A., Yusof M.M., Gallardo C., Lipatov O., Barrios C.H., Holgado E., et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): A randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396:1817–1828. doi: 10.1016/S0140-6736(20)32531-9. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources